Talha Badar, MD

Conference Coverage

Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML

01/03/2024

Talha Badar , MD;

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

01/03/2024

Oncology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Talha Badar, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products